- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
R2 Technology registers for IPO
Privately held R2 Technology has taken the first step toward going public. The pioneer of computer-assisted diagnosis has filed a registration statement with the Securities and
Privately held R2 Technology has taken the first step toward going public. The pioneer of computer-assisted diagnosis has filed a registration statement with the Securities and Exchange Commission for an initial public offering of common stock. Net proceeds will be used for general corporate purposes, including working capital, R&D, sales and marketing, clinical and regulatory studies, and capital expenditures. A portion may also be used to acquire or invest in complementary businesses, products, and technologies. R2 develops, manufactures, and sells proprietary medical systems to assist radiologists in the detection of cancer. The company's ImageChecker CAD system analyzes medical images, marking features that may indicate cancer. Prior to the registration, the company secured $14 million in venture capital financing. That round brought the total of VC financing to $76 million since the company was incorporated in 1993.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.
Emerging MRI Scoring System May Help Predict Recurrent and Metastatic Hepatocellular Carcinoma
February 12th 2025Preoperative use of the scoring system for gadoxetic acid-enhanced MRI demonstrated an average AUC of 85 percent and average specificity of 89 percent in external validation cohorts for pathologic features of hepatocellular carcinoma.
Key Chest CT Parameters for Body Composition May be Prognostic for Patients with Resectable NSCLC
February 11th 2025A high intermuscular adipose index has a 49 percent increased likelihood of being associated with lower overall survival in patients with resectable non-small cell lung cancer (NSCLC), according to new research.
